Reversal of T1D in NOD mice using a safe combination therapy View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2012-2016

FUNDING AMOUNT

1328078 USD

ABSTRACT

DESCRIPTION (provided by applicant): Antigen-based therapies (ABTs) for autoimmune disease are theoretically appealing because they can induce regulatory responses with little interference with immune system function. While ABTs effectively prevent type 1 diabetes (T1D) in NOD mice, ABTs have little to no ability to slow disease progression after NOD mice develop mild hyperglycemia. Moreover, in human clinical trials, ABT's have thus far not shown a significant ability to preserve residual insulin production in individuals newly diagnosed with T1D. Therefore, there is an urgent need to further develop ABTs in combination with other safe therapeutics to better protect remaining ss-cells in newly diabetic animals. In particular, it willbe critical to reduce inflammatory autoimmune responses, promote regulatory responses and promote ss-cell restoration. We propose a safe combination therapy which achieves all these aims. The activation of immune cell g-aminobutyric acid (GABA) receptors (GABA-Rs) has been shown to prevent T1D, experimental autoimmune encephalomyelitis (EAE) and rheumatoid arthritis in mouse models. Based on GABA's ability to inhibit inflammatory responses in different autoimmune diseases and its excellent safety profile, we tested the ability of combined ABT and GABA therapy to preserve syngenic islet grafts mice in diabetic NOD mice, as well as to reverse hyperglycemia in newly diabetic NOD mice. We found that in combination, these treatments act synergistically to prolong ss-cell survival in diabetic NOD mice. Our pilot studies suggest that the activation of GABAA-Rs on T cells also offers a new pathway to promote Treg expansion in vivo. Moreover work from our other studies demonstrate that GABA protects ss-cells from oxidative stress-induced apoptosis and promotes hyperglycemia-induced ss-cell replication. Thus, ABTs and GABA treatments are expected to work by mechanisms that are independent and mutually complementary. We will test the ability of different ss-cell antigens+GABA to reverse hyperglycemia in newly diabetic mice and determine the mechanisms by which ABT+GABA reverses T1D in NOD mice. We will test the hypotheses that 1) combined ABT+GABA treatment inhibits Th1 responses and promotes regulatory T cell responses and 2) that ABT+GABA treatment promotes ss-cell replication. Additionally, because little is known about the biology of GABA-receptors on immune cells, we will characterize GABA-receptors on different immune cell populations and how activation of GABA-Rs affects stimulation-mediated intracellular signaling. These studies will provide the preclinical information needed to initiate clinical trials of a combined therapeutic strategy that s urgently needed given the failure of monotherapies to preserve residual insulin production in newly diabetic individuals. We also expect to identify new pharmacological approaches to help expand Tregs and modulate effector T cells and APCs in ways that will be beneficial for inhibiting T1D as well as other T-cell mediated autoimmune diseases. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=8842979

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "1328078"
    }, 
    "description": "DESCRIPTION (provided by applicant): Antigen-based therapies (ABTs) for autoimmune disease are theoretically appealing because they can induce regulatory responses with little interference with immune system function. While ABTs effectively prevent type 1 diabetes (T1D) in NOD mice, ABTs have little to no ability to slow disease progression after NOD mice develop mild hyperglycemia. Moreover, in human clinical trials, ABT's have thus far not shown a significant ability to preserve residual insulin production in individuals newly diagnosed with T1D. Therefore, there is an urgent need to further develop ABTs in combination with other safe therapeutics to better protect remaining ss-cells in newly diabetic animals. In particular, it willbe critical to reduce inflammatory autoimmune responses, promote regulatory responses and promote ss-cell restoration. We propose a safe combination therapy which achieves all these aims. The activation of immune cell g-aminobutyric acid (GABA) receptors (GABA-Rs) has been shown to prevent T1D, experimental autoimmune encephalomyelitis (EAE) and rheumatoid arthritis in mouse models. Based on GABA's ability to inhibit inflammatory responses in different autoimmune diseases and its excellent safety profile, we tested the ability of combined ABT and GABA therapy to preserve syngenic islet grafts mice in diabetic NOD mice, as well as to reverse hyperglycemia in newly diabetic NOD mice. We found that in combination, these treatments act synergistically to prolong ss-cell survival in diabetic NOD mice. Our pilot studies suggest that the activation of GABAA-Rs on T cells also offers a new pathway to promote Treg expansion in vivo. Moreover work from our other studies demonstrate that GABA protects ss-cells from oxidative stress-induced apoptosis and promotes hyperglycemia-induced ss-cell replication. Thus, ABTs and GABA treatments are expected to work by mechanisms that are independent and mutually complementary. We will test the ability of different ss-cell antigens+GABA to reverse hyperglycemia in newly diabetic mice and determine the mechanisms by which ABT+GABA reverses T1D in NOD mice. We will test the hypotheses that 1) combined ABT+GABA treatment inhibits Th1 responses and promotes regulatory T cell responses and 2) that ABT+GABA treatment promotes ss-cell replication. Additionally, because little is known about the biology of GABA-receptors on immune cells, we will characterize GABA-receptors on different immune cell populations and how activation of GABA-Rs affects stimulation-mediated intracellular signaling. These studies will provide the preclinical information needed to initiate clinical trials of a combined therapeutic strategy that s urgently needed given the failure of monotherapies to preserve residual insulin production in newly diabetic individuals. We also expect to identify new pharmacological approaches to help expand Tregs and modulate effector T cells and APCs in ways that will be beneficial for inhibiting T1D as well as other T-cell mediated autoimmune diseases.", 
    "endDate": "2016-04-30T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.419635.c", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2500458", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2500458"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01DK092480"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "effector T cells", 
      "cell replication", 
      "excellent safety profile", 
      "preclinical information", 
      "GABA", 
      "reversal", 
      "ability", 
      "aim", 
      "APC", 
      "other studies", 
      "aminobutyric acid", 
      "way", 
      "type 1 diabetes", 
      "apoptosis", 
      "pilot study", 
      "little interference", 
      "regulatory responses", 
      "ss-cells", 
      "ss-cell replication", 
      "diabetic animals", 
      "inflammatory response", 
      "clinical trials", 
      "mild hyperglycemia", 
      "syngenic islet grafts mice", 
      "ABT+GABA treatment", 
      "experimental autoimmune encephalomyelitis", 
      "failure", 
      "new pathway", 
      "antigen", 
      "inflammatory autoimmune response", 
      "cell responses", 
      "work", 
      "ABT+GABA", 
      "other safe therapeutics", 
      "GABAA-Rs", 
      "GABA's ability", 
      "cells", 
      "monotherapies", 
      "different autoimmune diseases", 
      "study", 
      "stimulation", 
      "combined therapeutic strategies", 
      "ABT", 
      "diabetic mice", 
      "Treg expansion", 
      "hyperglycemia", 
      "cell survival", 
      "vivo", 
      "T1D.", 
      "oxidative stress", 
      "biology", 
      "immune cell g", 
      "GABA treatment", 
      "GABA-Rs", 
      "different ss-cell antigens+GABA", 
      "receptors", 
      "diabetic individuals", 
      "ABTS", 
      "disease progression", 
      "GABA therapy", 
      "new pharmacological approaches", 
      "hypothesis", 
      "rheumatoid arthritis", 
      "therapy", 
      "different immune cell populations", 
      "ss-cell restoration", 
      "NOD mice", 
      "human clinical trials", 
      "autoimmune diseases", 
      "diabetic NOD mice", 
      "mechanism", 
      "Tregs", 
      "applicants", 
      "safe combination therapy", 
      "description", 
      "residual insulin production", 
      "intracellular signaling", 
      "combination", 
      "mouse model", 
      "significant ability", 
      "individuals", 
      "immune system function", 
      "urgent need", 
      "Th1 responses", 
      "treatment", 
      "immune cells", 
      "GABA-receptors", 
      "T1D", 
      "activation"
    ], 
    "name": "Reversal of T1D in NOD mice using a safe combination therapy", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.19006.3e", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.19006.3e", 
          "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", 
          "type": "Organization"
        }, 
        "familyName": "KAUFMAN", 
        "givenName": "DANIEL", 
        "id": "sg:person.01054157465.50", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01054157465.50", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2500458"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_8.xml.gz", 
    "startDate": "2012-05-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=8842979"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2500458'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2500458'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2500458'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2500458'


 

This table displays all metadata directly associated to this object as RDF triples.

133 TRIPLES      19 PREDICATES      111 URIs      103 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2500458 schema:about anzsrc-for:2211
2 schema:amount N5c8dd17a69fa43a794530de48ccf1bc3
3 schema:description DESCRIPTION (provided by applicant): Antigen-based therapies (ABTs) for autoimmune disease are theoretically appealing because they can induce regulatory responses with little interference with immune system function. While ABTs effectively prevent type 1 diabetes (T1D) in NOD mice, ABTs have little to no ability to slow disease progression after NOD mice develop mild hyperglycemia. Moreover, in human clinical trials, ABT's have thus far not shown a significant ability to preserve residual insulin production in individuals newly diagnosed with T1D. Therefore, there is an urgent need to further develop ABTs in combination with other safe therapeutics to better protect remaining ss-cells in newly diabetic animals. In particular, it willbe critical to reduce inflammatory autoimmune responses, promote regulatory responses and promote ss-cell restoration. We propose a safe combination therapy which achieves all these aims. The activation of immune cell g-aminobutyric acid (GABA) receptors (GABA-Rs) has been shown to prevent T1D, experimental autoimmune encephalomyelitis (EAE) and rheumatoid arthritis in mouse models. Based on GABA's ability to inhibit inflammatory responses in different autoimmune diseases and its excellent safety profile, we tested the ability of combined ABT and GABA therapy to preserve syngenic islet grafts mice in diabetic NOD mice, as well as to reverse hyperglycemia in newly diabetic NOD mice. We found that in combination, these treatments act synergistically to prolong ss-cell survival in diabetic NOD mice. Our pilot studies suggest that the activation of GABAA-Rs on T cells also offers a new pathway to promote Treg expansion in vivo. Moreover work from our other studies demonstrate that GABA protects ss-cells from oxidative stress-induced apoptosis and promotes hyperglycemia-induced ss-cell replication. Thus, ABTs and GABA treatments are expected to work by mechanisms that are independent and mutually complementary. We will test the ability of different ss-cell antigens+GABA to reverse hyperglycemia in newly diabetic mice and determine the mechanisms by which ABT+GABA reverses T1D in NOD mice. We will test the hypotheses that 1) combined ABT+GABA treatment inhibits Th1 responses and promotes regulatory T cell responses and 2) that ABT+GABA treatment promotes ss-cell replication. Additionally, because little is known about the biology of GABA-receptors on immune cells, we will characterize GABA-receptors on different immune cell populations and how activation of GABA-Rs affects stimulation-mediated intracellular signaling. These studies will provide the preclinical information needed to initiate clinical trials of a combined therapeutic strategy that s urgently needed given the failure of monotherapies to preserve residual insulin production in newly diabetic individuals. We also expect to identify new pharmacological approaches to help expand Tregs and modulate effector T cells and APCs in ways that will be beneficial for inhibiting T1D as well as other T-cell mediated autoimmune diseases.
4 schema:endDate 2016-04-30T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.419635.c
6 schema:identifier N3b300de7473f46709c865e3d3390c94a
7 Nfad1f222f73e4a1e831797fa755c4130
8 schema:inLanguage en
9 schema:keywords ABT
10 ABT+GABA
11 ABT+GABA treatment
12 ABTS
13 APC
14 GABA
15 GABA therapy
16 GABA treatment
17 GABA's ability
18 GABA-Rs
19 GABA-receptors
20 GABAA-Rs
21 NOD mice
22 T1D
23 T1D.
24 Th1 responses
25 Treg expansion
26 Tregs
27 ability
28 activation
29 aim
30 aminobutyric acid
31 antigen
32 apoptosis
33 applicants
34 autoimmune diseases
35 biology
36 cell replication
37 cell responses
38 cell survival
39 cells
40 clinical trials
41 combination
42 combined therapeutic strategies
43 description
44 diabetic NOD mice
45 diabetic animals
46 diabetic individuals
47 diabetic mice
48 different autoimmune diseases
49 different immune cell populations
50 different ss-cell antigens+GABA
51 disease progression
52 effector T cells
53 excellent safety profile
54 experimental autoimmune encephalomyelitis
55 failure
56 human clinical trials
57 hyperglycemia
58 hypothesis
59 immune cell g
60 immune cells
61 immune system function
62 individuals
63 inflammatory autoimmune response
64 inflammatory response
65 intracellular signaling
66 little interference
67 mechanism
68 mild hyperglycemia
69 monotherapies
70 mouse model
71 new pathway
72 new pharmacological approaches
73 other safe therapeutics
74 other studies
75 oxidative stress
76 pilot study
77 preclinical information
78 receptors
79 regulatory responses
80 residual insulin production
81 reversal
82 rheumatoid arthritis
83 safe combination therapy
84 significant ability
85 ss-cell replication
86 ss-cell restoration
87 ss-cells
88 stimulation
89 study
90 syngenic islet grafts mice
91 therapy
92 treatment
93 type 1 diabetes
94 urgent need
95 vivo
96 way
97 work
98 schema:name Reversal of T1D in NOD mice using a safe combination therapy
99 schema:recipient N4a8d4aa195034e9abeb5e674502fa05c
100 sg:person.01054157465.50
101 https://www.grid.ac/institutes/grid.19006.3e
102 schema:sameAs https://app.dimensions.ai/details/grant/grant.2500458
103 schema:sdDatePublished 2019-03-07T12:16
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher Ncee3dc2667b64e1a833b574ed85faafb
106 schema:startDate 2012-05-01T00:00:00Z
107 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=8842979
108 sgo:license sg:explorer/license/
109 sgo:sdDataset grants
110 rdf:type schema:MonetaryGrant
111 N3b300de7473f46709c865e3d3390c94a schema:name dimensions_id
112 schema:value 2500458
113 rdf:type schema:PropertyValue
114 N4a8d4aa195034e9abeb5e674502fa05c schema:member sg:person.01054157465.50
115 schema:roleName PI
116 rdf:type schema:Role
117 N5c8dd17a69fa43a794530de48ccf1bc3 schema:currency USD
118 schema:value 1328078
119 rdf:type schema:MonetaryAmount
120 Ncee3dc2667b64e1a833b574ed85faafb schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 Nfad1f222f73e4a1e831797fa755c4130 schema:name nih_id
123 schema:value R01DK092480
124 rdf:type schema:PropertyValue
125 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
126 rdf:type schema:DefinedTerm
127 sg:person.01054157465.50 schema:affiliation https://www.grid.ac/institutes/grid.19006.3e
128 schema:familyName KAUFMAN
129 schema:givenName DANIEL
130 rdf:type schema:Person
131 https://www.grid.ac/institutes/grid.19006.3e schema:name UNIVERSITY OF CALIFORNIA LOS ANGELES
132 rdf:type schema:Organization
133 https://www.grid.ac/institutes/grid.419635.c schema:Organization
 




Preview window. Press ESC to close (or click here)


...